These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
3. The Effects of Long-Acting Stimulant and Nonstimulant Medications in Children and Adolescents with Attention-Deficit/Hyperactivity Disorder: A Meta-Analysis of Randomized Controlled Trials. Cerrillo-Urbina AJ; García-Hermoso A; Pardo-Guijarro MJ; Sánchez-López M; Santos-Gómez JL; Martínez-Vizcaíno V J Child Adolesc Psychopharmacol; 2018 Oct; 28(8):494-507. PubMed ID: 29897263 [TBL] [Abstract][Full Text] [Related]
4. Attention-deficit/hyperactivity disorder: using P300 topography to choose optimal treatment. Sangal RB; Sangal JM Expert Rev Neurother; 2006 Oct; 6(10):1429-37. PubMed ID: 17078784 [TBL] [Abstract][Full Text] [Related]
5. Effects of osmotic-release methylphenidate in attention-deficit/hyperactivity disorder as measured by event-related potentials. Sawada M; Iida J; Ota T; Negoro H; Tanaka S; Sadamatsu M; Kishimoto T Psychiatry Clin Neurosci; 2010 Oct; 64(5):491-8. PubMed ID: 20923428 [TBL] [Abstract][Full Text] [Related]
6. [Cognitive evoked potentials in the hyperactivity attention deficit disorder]. Idiazábal Alecha M; Palencia Taboada AB; Sangorrín J; Espadaler-Gamissans JM Rev Neurol; 2002 Feb 16-28; 34(4):301-5. PubMed ID: 12022041 [TBL] [Abstract][Full Text] [Related]
7. Event-related wave activity in the EEG provides new marker of ADHD. Alexander DM; Hermens DF; Keage HA; Clark CR; Williams LM; Kohn MR; Clarke SD; Lamb C; Gordon E Clin Neurophysiol; 2008 Jan; 119(1):163-79. PubMed ID: 18054279 [TBL] [Abstract][Full Text] [Related]
8. Cost effectiveness of guanfacine extended release as an adjunctive therapy to a stimulant compared with stimulant monotherapy for the treatment of attention-deficit hyperactivity disorder in children and adolescents. Sikirica V; Haim Erder M; Xie J; Macaulay D; Diener M; Hodgkins P; Wu EQ Pharmacoeconomics; 2012 Aug; 30(8):e1-15. PubMed ID: 22788263 [TBL] [Abstract][Full Text] [Related]
9. Event-related potentials reflect the efficacy of pharmaceutical treatments in children and adolescents with attention deficit/hyperactivity disorder. Yamamuro K; Ota T; Iida J; Nakanishi Y; Matsuura H; Uratani M; Okazaki K; Kishimoto N; Tanaka S; Kishimoto T Psychiatry Res; 2016 Aug; 242():288-294. PubMed ID: 27318633 [TBL] [Abstract][Full Text] [Related]
10. Adults with ADHD. An overview. Wender PH; Wolf LE; Wasserstein J Ann N Y Acad Sci; 2001 Jun; 931():1-16. PubMed ID: 11462736 [TBL] [Abstract][Full Text] [Related]
11. Risk of serious cardiovascular problems with medications for attention-deficit hyperactivity disorder. Martinez-Raga J; Knecht C; Szerman N; Martinez MI CNS Drugs; 2013 Jan; 27(1):15-30. PubMed ID: 23160939 [TBL] [Abstract][Full Text] [Related]
12. Understanding the effects of stimulant medications on cognition in individuals with attention-deficit hyperactivity disorder: a decade of progress. Swanson J; Baler RD; Volkow ND Neuropsychopharmacology; 2011 Jan; 36(1):207-26. PubMed ID: 20881946 [TBL] [Abstract][Full Text] [Related]
13. [Neurofunctional differences in the P300 frequency for multi-sensory stimulation in kids with attention deficit hyperactivity disorder]. Soria-Claros AM; Serrano I; Serra A; Félix M; Quintero J; Ortiz T Rev Neurol; 2015 Feb; 60 Suppl 1():S75-80. PubMed ID: 25726828 [TBL] [Abstract][Full Text] [Related]
14. Effect of psychostimulants on distinct attentional parameters in attentional deficit/hyperactivity disorder. López J; López V; Rojas D; Carrasco X; Rothhammer P; García R; Rothhammer F; Aboitiz F Biol Res; 2004; 37(3):461-8. PubMed ID: 15515970 [TBL] [Abstract][Full Text] [Related]